viewTissue Regenix Group PLC

Tissue Regenix sees strong demand for product portfolio


  • Products spanning wound care, orthopaedics and cardiac application
  • Focused on boosting sales after capacity boost
  • Operations split between the UK and US 
Tissue Regenix Group PLC -

Quick facts: Tissue Regenix Group PLC

Price: 0.33 GBX

Market: AIM
Market Cap: £23.21 m

What it does

Regenerative medical devices maker Tissue Regenix PLC (LON:TRX) has products spanning wound care, orthopaedics and cardiac applications, which are based on two proven technologies.

The first, dCELL, removes cellular and DNA material from biological tissues, leaving intact a scaffold upon which the patient's cells can regenerate and re-populate.

The AIM-listed company, which was spun out from the University of Leeds in 2006, uses dCELL Technology in its DermaPure product for the healing of chronic wounds.

The other technology, BioRinse, does a similar job, killing micro-organisms, bacteria and spores as well as removing debris, blood, bone marrow and lipids.

It is key to the process used to create regenerative scaffolds used by surgeons developed by CellRight – the Texas-based biotech Tissue Regenix bought in August 2017.

CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures to enhance healing of defects caused by trauma or disease.


How it is doing

In June its OrthoPure XT product received the CE marking for revision of the anterior cruciate ligament following re-rupture and also permits use for the reconstruction of other knee ligaments, including multi-ligament procedures following trauma.

It also received over US$1mln in US government aid during the pandemic, while it raised £14.6mln via a placing of shares to fund the group's manufacturing capacity expansion programme.

Revenues for the first quarter rose 18% despite a cyberattack on its facility in San Antonio, Texas.

For the year ended December 31, the regenerative medicine specialist posted a 12% rise in revenues to £13.03mln and narrowed its operating loss to £7.2mln from £8.69mln in the prior year.


What the boss says: Gareth Jones, interim chief executive 

"Whilst sales were not materially impacted during the first quarter, where we delivered 18% year-on-year growth, the board is unable to provide clarity on the financial outlook for 2020 until there is greater visibility around the impact of the COVID-19 pandemic in the market."

"During  2019, recognising the need to optimise our supply chain and processes to address various operational challenges and support the growing demand for our products, we concentrated efforts on implementing a number of efficiency improvements which manifested in donor throughput more than doubling between Q1-Q4 2019 at the facility in San Antonio."

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...



Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read